Rituximab-Based Chemotherapy and
|
|
- Jason Dalton
- 8 years ago
- Views:
Transcription
1 用 藥 安 全 Drug Safety Rituximab-Based Chemotherapy and Late-Onset Neutropenia Yi-Ling Lu, Wan-Tsui Huang, Chi-Lan Kao, Hsi-Yen Lin Department of Pharmacy, Cathay General Hospital, Taipei, Taiwan Abstract Rituximab is a human/mouse chimeric anti-cd20 antibody, used as monotherapy or in combination with chemotherapy for B-cell non-hodgkin's lymphoma. The most common adverse effects are infusion-related reactions (fever, chills, and urticaria) that usually occur within a few hours after infusion. Hematological adverse effects have been observed in patients receiving rituximab monotherapy, but delayed-onset neutropenia is relatively uncommon. Here we report a case of febrile delayed-onset grade 4 neutropenia associated with rituximab combination with CHOP chemotherapy (R-CHOP). A 32 year-old female, 29 days after receiving the 7 th cycle of R-CHOP developed fever and chills, and febrile delayedonset neutropenia was suspected. Antibiotic and G-CSF were used, the response to G-CSF diminished and the duration of G-CSF usage prolonged to meet the need for neutrophil recovery to normal level. After rule out other causes such as infections, the result of bone marrow examination, the Naranjo probability test revealed a probable correlation, and no other medications used during the episode of neutropenia, the episode was highly suspected to be rituximab-related in the R-CHOP regimen. Although rituximab-induced delayed-onset neutropenia is uncommon, it should still be kept in mind. Accordingly, the blood cell count should be monitored for a longer duration. Although G-CSF is not recommended by the ASCO guideline, in our case, G-CSF seems helpful, we thought it would be better to administer it for prophylaxis rather than for treatment. Key words: rituximab, delayed-onset neutropenia, G-CSF Introduction Rituximab is a human/mouse chimeric anti-cd20 antibody, which is indicated for the treatment of patients with CD20-positive B-cell 108 THE JOURNAL OF TAIWAN PHARMACY Vol.27 No.2 Jun
2 Rituximab-Based Chemotherapy and Late-Onset Neutropenia non-hodgkin's lymphoma (NHL). Rituxmab is used as monotherapy or in combination with CVP (cyclophosphamide, vincristine, prednisolone) chemotherapy for low-grade or follicular NHL, and in combination with CHOP (cyclophosphamide, low-dose doxorubicin, vincristine, prednisolone) chemotherapy for diffuse large B-cell NHL. The most common adverse effects are infusion-related reactions (fever, chills, and urticaria) that usually occurred within a few hours of starting the first infusion. In clinical trials, grade 3 and 4 hematological adverse effects including neutropenia (4.2%), leukopenia (2.8%), and thrombocytopenia (1.7%) had been observed in patients receiving rituximab monotherapy. During post-marketing surveillance from manufacturer, rare delayed-onset neutropenia (0.02% rate) had also been noticed, which occurred more than 4 weeks after the last infusion of rituximab. Thereafter, more and more cases of delayed-onset neutropenia of rituximab use were reported 1-4. Recently, a study in Japan suggested that the incidence of delayed-onset grade 3 and 4 neutropenia was as high as 20.4% after rituximab-containing chemotherapy 5. In Taiwan, no similar study published, here we report a case of febrile delayed-onset grade 4 neutropenia associated with rituximab combination with CHOP chemotherapy. Case Report A 32 year-old female was diagnosed to have diffuse large B cell lymphoma according to the World Health Organization classification of lymphoid malignancies and CD20- positive lymphoma was confirmed. Eight cycles of standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) every 3 weeks plus rituximab regimen (R-CHOP) were scheduled. Each cycle consisted of intravenous injection of rituximab 375 mg/m 2 (600 mg) on day 1, on day 3, cyclophosphamide 750 mg/ m 2 (1200 mg), doxorubicin 50 mg/m 2 (80 mg), and vincristine 1.4 mg/m 2 (2 mg) were added. Prednisolone 100 mg was also given orally per day from day 3 to day 7. Since the third cycle of R-CHOP, febrile grade 4 neutropenia occurred and she was then given one dose of granulocytecolony stimulating factor (G-CSF) 300 mcg subcutaneously. In the following four cycles, more doses of G-CSF per cycle were needed to reach the same response, hence the dosage of G-CSF was escalatory to 3 or 6 doses per cycle. Twenty-nine days after the seventh cycle, the patient presented with fever and chills. No other prescription medications were used within that period. Physical examination showed body temperature of 38.9, blood pressure 110/70 mmhg, heart rate 100 beats/min, and respiration rate 18 breaths/min. Laboratory tests revealed white blood cell count 2.19 x 10 3 / mm 3 (reference range x 10 3 /mm 3 ), absolute neutrophil count (ANC) 44/mm 3, red blood cell count 3.86 x 10 6 /mm 3 (reference range x 10 6 /mm 3 ), platelet count 335 x 10 3 /mm 3 (reference range x 10 3 / mm 3 ), and the level of C-reactive protein was 4.46 mg/l (reference range 0-1 mg/l). As a febrile grade 4 neutropenia was diagnosed, she was then hospitalized and the eighth cycle of 27 2 Jun 藥 學 雜 誌
3 用 藥 安 全 Drug Safety chemotherapy was not given. Empirical antibiotic therapy with intravenous cefepime 2g every 12-hour intervals for 7 days was initiated. Bone marrow aspiration showed myeloid hypoplasia. Blood and bone marrow cultures yielded no growth of aerobic pathogens. Both cytomegalovirus (CMV) and Epstein-Barr virus (EBV) titers were negative for active infection. The patient had persistent fever with maximum temperature of 39.4 throughout the first 3 days. Although no specific pathogen was identified, the antibiotic regimen was shifted to a combination therapy, adding intravenous clindamycin 600mg every 8 h for 7 days starting from hospital day 3. During hospitalization, she was treated with G-CSF 300 mcg s.c. daily for 3 days, and neutropenia resolved within 4 days. The medications used during hospitalization, physical findings, results of laboratory tests and the responses of neutrophil to G-CSF are listed in Table 1-3 and Figure 1. Table 1 Medications used during hospitalization Medications and dosage date 1/ Cefepime i.v. 2 g q12h Clindamycin i.v. 600 mg q8h G-CSF s.c. 300 mcg qd Acetaminophen 500 mg 1 # prn x 1 x 4 x 3 qd qd qd qd qd Metoclopramide 5 mg st Sennoside 2 # hs Table 2 Cultures during hospitalization Items Date results 1/12 1/12 1/18 Specimens Blood Bone Marrow Cultures Negative Negative Sensitivity tests No aerobic pathogen No aerobic pathogen CMV IgG Ab (+) CMV IgM Ab (-) 0.15 E-B VCA IgM Ab (-) 0.02 UGI panendoscope Colonoscopy Negative Colon polyps 110 THE JOURNAL OF TAIWAN PHARMACY Vol.27 No.2 Jun
4 Rituximab-Based Chemotherapy and Late-Onset Neutropenia Table 3 Laboratory tests during hospitalization Items Normal levels dates 1/12 1/13 1/14 1/15 1/16 1/18 1/20 WBC *10 3 /cell/mm Seg % Band 0-5 % ANC Lympho S % Mono % Eos 0-7 % Baso % RBC *10 6 /cell/mm Hb g/dl Ht % MCV fl MCH Pg MCHC g/dl PLT *10 3 /cell/mm Promyelocyte % Myelocyte % Metamyelocyte % NRBC 1 BUN 8-25 mg/dl Scr mg/dl GOT/GPT 5-35 IU/L 17/13 37/17 LDH IU/L 273 Na meq/dl K meq/dl CRP 0-1 mg/l Jun 藥 學 雜 誌
5 用 藥 安 全 Drug Safety Fig. 1 Responses of neutrophils to G-CSF injections. Discussion R i t u x i m a b c o m b i n e d w i t h C H O P chemotherapy is the standard regimen that serves as the first-line treatment for diffuse B-cell lymphoma. The results of clinical trials suggest that rituximab might increase the rate of complete response, prolong event-free and overall survival, and reduce the risk of treatment failure and death to CHOP regimen without a clinically significant increase in toxicity 6-8. According to the manufacturer, the incidence of grade 3 and 4 neutropenia was slightly higher in the R-CHOP group (97%) than in the CHOP group (88%) 8, but no difference between the two-treatment groups was noted in grade 2 to 4 infections (55.4% for R-CHOP vs 51.5% for CHOP). Delayed-onset of grade 4 neutropenia is a vague complication of treatment with rituximab-based chemotherapy, which is defined when the ANC is less than 0.5 x 10 3 / mm 3 [according to the National Center Institute (NCI) Common Toxicity Criteria] and the adverse effect that occurred more than 4 weeks after the last infusion of rituximab. I n p r e v i o u s l y p u b l i s h e d r e p o r t s, delayed-onset grade 4 neutropenia caused by rituximab alone or rituximab chemotherapy usually occurred within 28 to 175 days after administration and the nadir neutrophil count usually ranged from 0.02 x 10 3 /mm 3 to 0.39 x 10 3 /mm 3 1,4,9. A study of 53 patients showed that there was a high incidence of delayedonset grade 4 neutropenia (15%) observed within 1 and 5 months, the characteristics of neutropenic episode included fever, infections (buccal cellulites, pneumonia, upper respiratory 112 THE JOURNAL OF TAIWAN PHARMACY Vol.27 No.2 Jun
6 Rituximab-Based Chemotherapy and Late-Onset Neutropenia infection), and some may even occur asymptomatically 1. The mechanism for developing delayedonset grade 4 neutropenia after rituximab remains unknown, but previous studies suggested it may be immune-mediated 1,4,9. It is unlikely that rituximab causes severe neutropenia directly, due to the absence of CD20-coated neutrophils and hematopoietic cells 8. Possible mechanisms include production of antineutrophil antibodies, apoptosis of mature neutrophils by the secretion of Fas (a molecule expressed on a variety of cells, which acts as a target for ligation by FasL on the surface of cytotoxic lymphocytes) related to hyperproliferation of large granular T cells, and immune dysfunction 1,9. However Fukuno et al failed to identify antineutrophil antibody or immune complex during 3 episodes after rituximab therapy 4. Additionally, the perturbation of stromal derived factor-1 (SDF- 1) is associated with rapid B cell recovery and retardant neutrophil egress from the bone marrow following rituximab-basd therapy 10. The authors demonstrated that delayed-onset neutropenia is self-limited and does not cause significant clinical events 4,10. In our patient, throughout the third and subsequent cycles of chemotherapy, episodes of grade 4 neutropenia with or without fever occurred about 1 week after treatment with R-CHOP regimen, and administration of G-CSF seemed to be helpful for ANC recovery to normal level. But more doses of G-CSF were needed for the later cycles. During the seventh cycle of R-CHOP chemotherapy, although 6 daily consecutive doses of G-CSF were given, the ANC did not recover as anticipated, but further decreased dramatically and grade 4 neutropenia on day 29 was found. Use of the Naranjo probability scale indicated a probable relationship between R - C H O P a n d d e l a y e d - o n s e t g r a d e 4 neutropenia in our patient 11. In addition, the bone marrow aspiration in our patient showed disturbance of myeloid maturation rather than myelosuppression for cytotoxic agents. These findings indicate that rituximab likely induce delayed-onset grade 4 neutropenia. The necessity of G-CSF supported in literature reviews of delayed-onset grade 4 neutropenia remains controversial. The American Society of Clinical Oncology (ASCO) guidelines for the use of hematopoietic colonystimulating factors (CSFs) recommend that CSFs should not be routinely used as adjuvant therapy for the treatment of uncomplicated fever and neutropenia 12. However, other reports implied that delayed-onset febrile neutropenia have been resolved by using G-CSF when the ANC nadir was less than 0.06 x 10 3 /mm 3 1,9. It has been reported that the subsequent cycles of R-CHOP chemotherapy could be treated with G-CSF as prophylaxis for subsequent cycles of chemotherapy after an episode of febrile neutropenia 7. Our patient was treated with G-CSF when the neutropenia developed again. Consequently the responses of ANC were not acceptable until the dose of G-CSF was escalated. A study suggested that a decrease of the dose of cyclophosphamide and doxorubicin by 50 percent should be considered when grade 27 2 Jun 藥 學 雜 誌
7 用 藥 安 全 Drug Safety 4 neutropenia persisted during the next cycle. Nevertheless, the ANC was less than 1.5 x 10 3 / mm 3 before a scheduled cycle, the cycle might be delayed for up to 2 weeks 7. Furthermore, the neutrophil count should be monitored over an 8-week period following rituximab therapy. A randomized phase II study recognized that although major hematological toxicity was neutropenia and grade 4 neutropenia was observed in 85% of patients receiving standard R-CHOP chemotherapy, these hematological adverse effects were manageable with or without using G-CSF 13. In our patient, since no other medications were used during the episode of neutropenia, and no other diseases were attributable to the cause of neutropenia, we highly suspect that the episode was riuximab-related in the R-CHOP regimen. Conclusions: Although rituximab-induced delayed-onset neutropenia is uncommon, physicians should keep in mind and monitor the blood cell count for a longer duration, and although G-CSF was not recommended by the ASCO guideline, in our case, G-CSF seems helpful and it would be better that G-CSF can be administered for prophylaxis rather than for treatment. References: 1. Chaiwatanatorn K, Lee N, Grigg A, et al: Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121: Motl SE, Baskin RC: Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review. Pharmacotherapy 2005; 25: Larrar S, Guitton C, Willems M, et al: Severe hematological side effects following Rituximab therapy in children. Haematologica 2006; 91(8 suppl): S Fukuno K, Tsurumi H, Ando N, et al: Late-onset neutropenia in patients treated with rituximab for non-hodgkin's lymphoma. Int J Hematol 2006; 84: Nitta E, Izutsu K, Sato T, et al: A high incidence of lateonset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007; 18: Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non- Hodgkin's lymphoma. J Clin Oncol 2001; 19: Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med 2002; 346: Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: Voog E, Morschhauser F, Solal-Céligny P: Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348: Dunleavy K, Hakim F, Kim HK, et al: B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005; 106: Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: Ozer H, Armitage JO, Bennett CL, et al: American Society of Clinical Oncology update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: Ogura M, Morishima Y, Kagami Y, et al: Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci 2006; 97: Rituximab CD-20 B Rituximab ( 4 ) Rituximab CHOP R-CHOP 4 32 B R-CHOP THE JOURNAL OF TAIWAN PHARMACY Vol.27 No.2 Jun
8 Rituximab-Based Chemotherapy and Late-Onset Neutropenia G-CSF G-CSF Naranjo Rituximab R-CHOP febrile neutropenia (FN) G-CSF FN 4 neutropenia cyclophosphamide doxorubicin ANC< 1500 cell/mm 3 2 rituximab 8 (ASCO) G-CSF 笑 佛 木 雕 ( 陳 守 雄 藥 師 提 供 ) 27 2 Jun 藥 學 雜 誌
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationSevere rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
More informationBendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationIn non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationDE Tsai 1, HCF Moore 1, CL Hardy 2, DL Porter 1, EY Loh 1, DJ Vaughn 1, S Luger 1, SJ Schuster 1 and EA Stadtmauer 1
Bone Marrow Transplantation, (1999) 24, 521 526 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt Rituximab (anti-cd20 monoclonal antibody) therapy for progressive
More informationDavid Loew, LCL MabThera
MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationNon-Hodgkin s lymphomas (NHLs) are a
Oncology 33 Non-Hodgkin s lymphoma in the elderly The incidence of non-hodgkin s lymphoma (NHL) is increasing, and this increase is even more rapid in the older population. Although treatment of NHL in
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationTwo Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,
More informationGuidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre
Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection
More informationDIFFUSE LARGE B-CELL LYMPHOMA
DIFFUSE LARGE B-CELL LYMPHOMA Executive Summary Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-hodgkin lymphoma (NHL), constituting up to 40% of all cases globally.[1] This subtype
More informationClair Clark, Cancer Care Pharmacist Beatson West of Scotland Cancer Centre
Clair Clark, Cancer Care Pharmacist Beatson West of Scotland Cancer Centre An audit of neutropenic complications in breast cancer patients receiving adjuvant or neo-adjuvant chemotherapy with FEC-D in
More informationCycle frequency: Every four weeks Total number of cycles: 6-8
Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and
More informationPractice of Interferon Therapy
Interferon Therapy Practice of Interferon Therapy Multiple myeloma and other related hematological malignancies JMAJ 47(1): 32 37, 2004 Akihisa KANAMARU* and Takashi ASHIDA** *Professor, **Lecturer, Department
More informationGRANIX (tbo-filgrastim)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil
More informationrituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited
rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited 06 June 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationRituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma
Issue date: June 2011 Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma This guidance was developed using the the single technology appraisal process NICE technology
More informationTherapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma
a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University
More informationLymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
More informationAnti-HCV therapy in HCV-related NHL
Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationWhat is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationRituximab in the Management of Follicular Lymphoma
Hong Kong J Radiol. 2011;14(Suppl):S63-7 REVIEW ARTICLE Rituximab in the Management of Follicular Lymphoma YL Kwong Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationGuidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationLymphoma: The Roleof Nurses in the Treatment Process
Lymphoma: The Roleof Nurses in the Treatment Process Sarah Liptrott MSc,BN(Hons), RN Istituto Europeo di Oncologia, Milan (IT) EBMT Swiss Study Day 2014, Zurich, Switzerland LymphomaManagement Watch &
More informationSupplementary Online Content
Supplementary Online Content Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving
More informationKeywords: Rituximab; Drug therapy; Lymphoma, non-hodgkin; Adverse effects; Lung diseases, interstitial
ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.1.86 Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationRituximab in non-hodgkin Lymphoma (NHL)
Original Article ISSN: 2070-254X Rituximab in non-hodgkin Lymphoma (NHL) Manal Elhabbash MD 1, Abukris Alwindi MD 2 (1) Assistant Professor, Tripoli University, (2) Medical consultant in oncology & hematology
More informationDocetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer
Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient
More informationBlood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationMOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress Rescue Chemotherapy Protocols for Dogs with Lymphoma Kenneth M. Rassnick, DVM, DACVIM (Oncology) Cornell University
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationYour NHL Journey. RITUXAN for Follicular Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL) Indications. Important Safety Information
* Your NHL Journey RITUXAN for Follicular Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL) * Non-Hodgkin s Lymphoma Indications RITUXAN (rituximab) is indicated for the treatment of: Follicular CD20-positive
More informationLymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
More informationLeukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
More informationA 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
More informationNATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NATIONAL CANCER INSTITUTE Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Basic Trial Information Phase Type Status Age Sponsor Protocol IDs Phase
More informationMany people with non-hodgkin lymphoma have found an educational support group helpful. Support
Track 2: Treatment Options [Narrator] Many people with non-hodgkin lymphoma have found an educational support group helpful. Support groups take many forms: some meet the needs of people with all kinds
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More informationAdditional file 1. Progress of phase II clinical trials of Panagen
Additional file 1. Progress of phase II clinical trials of Panagen Documentation Phase II clinical trial of preparation Panagen was performed in compliance with the following documentation: Approval of
More informationLeukaemia and lymphoma what s the difference?
Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk Leukaemia and lymphoma what s the difference? This is a difficult question to answer simply but it is one that is often
More informationRituximab is a monoclonal chimeric antibody
Rituximab-Associated Neutropenia Kieron Dunleavy, Kevin Tay, and Wyndham H. Wilson Several recent studies have reported the phenomenon of late-onset neutropenia occurring usually several months following
More informationWM: Managing the Side Effects of Treatment
WM: Managing the Side Effects of Treatment 2014 IWMF Educational Forum Jeffrey V. Matous, MD Colorado Blood Cancer Institute www.bloodcancerinstitute.com Tampa, FL May 17, 2014 Determining a side effect
More informationCollect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.
Complete Blood Count CPT Code: CBC with Differential: 85025 CBC without Differential: 85027 Order Code: CBC with Differential: C915 Includes: White blood cell, Red blood cell, Hematocrit, Hemoglobin, MCV,
More informationEffective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin
More informationPhase II Trial of R -C H O P V s C H O P C hem otherapy in Pakistani D iffuse Large B cell Lym phom a Patients
Original Article Phase II Trial R -C H O P V s C H O P C hem otherapy in Pakistani D iffuse Large B cell Lym phom a Patients Objective: To determine response and relapse rates in diffuse large B cell lymphoma
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationJ Clin Oncol 22:4302-4311. 2004 by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 21 NOVEMBER 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin s Lymphoma: A Nationwide
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationMichael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto
Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory
More informationSalvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma
IMAJ VOL 11 January 9 Salvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma Ariela Dortort Lazar MD 1,, Ofer Shpilberg
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationoriginal article P. Jenkins 1 * & S. Freeman 2 introduction patients and methods original article
Annals of Oncology 20: 34 40, 2009 doi:10.1093/annonc/mdn560 Published online 13 August 2008 Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant
More informationCollaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular
More informationRITUXAN (rituximab) injection, for intravenous use Initial U.S. Approval: 1997
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for RITUXAN. RITUXAN (rituximab)
More informationOut-Patient Chemotherapy for Lung Cancer
Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent
More informationCytoreductive Therapy for Autologous Cell Therapy in HIV
Cytoreductive Therapy for Autologous Cell Therapy in HIV Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center) HSC Transfer from CCR5-delta 32 Donor
More informationJ Clin Oncol 23:8447-8452. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 33 NOVEMBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma Richard I. Fisher, Michael
More informationBCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)
BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) Protocol Code Tumour Group Contact Physician UGUTIP Genitourinary Dr.
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationHospital Outpatient Coding and Billing Information Sheet for Neulasta and NEUPOGEN
Hospital Outpatient Coding and Billing Information Sheet for Neulasta and Neulasta Delivery Kit Neulasta Prefilled Syringe For assistance contact 1-844-MYNEULASTA (1-844-696-3852) or visit www.amgenassistonline.com
More informationWaldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
More informationSummary & Conclusion
The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with
More informationRituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008
Rituximab in Non - Hodgkins Lymphoma Fatima Bassa, Dept. of Haematology October 2008 World Health Organization lymphoma classification (2001) Peripheral B-cell neoplasms: B-chronic lymphocytic leukemia/small
More informationBCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More information1. Introduction. 2. Clinical aspects
1. Introduction MabThera (rituximab) is a genetically engineered chimeric mouse/human monoclonal antibody which binds specifically to the transmembrane antigen, CD20. This antigen is located on pre-b-
More informationLYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
More informationHistopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
More informationUNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD
UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. Petitioner, v. Biogen Idec, Inc.
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationNew Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the
More informationThe role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D.
The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D. Oncology Institute of Southern Switzerland (IOSI) Swiss Group for Clinical Cancer Research (SAKK) WHO grading of follicular lymphoma
More informationFludarabine based chemotherapy [Fludarabine, FC, FCR, FMD]
Approved Haematology Chemotherapy Protocol Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD] MCCN Ref OPCS Proc OPCS Del CLFLUD X70.5 X72.3 IV CLFC X70.4 X72.2 IV X73.1 O CLFCR X71.5 X72.1 LYFMD
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationManaging Lymphoma. Professor Clare Knottenbelt BVSc MSc DSAM MRCVS
Managing Lymphoma Professor Clare Knottenbelt BVSc MSc DSAM MRCVS Lymphoma Common cancer (18% of dog cancers) DOGS: Multicentric CATS: Alimentary Presentation varies with site of LSA and paraneoplastic
More information